site stats

Jcog0211-di

WebYamaguchi, Motoko ; Tobinai, Kensei ; Oguchi, Masahiko et al. / Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma : An updated analysis of the Japan Clinical Oncology Group Study JCOG0211. In: Journal of Clinical Oncology. 2012 ; Vol. 30, No. 32. pp. 4044-4046. WebNK/T-cell lymphoma (NKTCL) in Japan • Incidence: 1.0 - 2.6% of ML • Median age at diagnosis: 58 years Lymphoma Study Group of Japanese Pathologists.

Phase I/II Study of Concurrent Chemoradiotherapy for

Web8 ott 2012 · In the November 20, 2009, issue of Journal of Clinical Oncology, we reported the results of our first analysis of a phase I/II study of concurrent chemoradiotherapy for newly diagnosed localized nasal NKTCL (Japan Clinical Oncology Group study JCOG0211). 3 Our first analysis demonstrated improved overall survival (OS) and progression-free … Web10 nov 2012 · Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211 J … tafe cert 3 horticulture https://laurrakamadre.com

NK/T-cell lymphoma: the role of asparaginase Japanese experience

Web– JCOG0211 (PI/II) – Concurrent chemoradiotherapy (RT-2/3DeVIC) • Newly-diagnosed stage IV, relapsed/refractory NKTCL – NKTSG (Multinational trials in East Asia) – SMILE-P1 & P2 – SMILE chemotherapy Yamaguchi M, Tobinai K, Oguchi M, et al. J Clin Oncol 2009, 2012 (correspondence) Yamaguchi M, Kwong YL, Kim WS, et al. J Clin Oncol 2011 Web10 mag 2010 · Concurrent chemoradiotherapy for limited-stage extranodal natural killer/t-cell lymphoma, nasal type WebPhase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, Matsuno Y, Terauchi T, Nawano S, Ishikura S, Kagami Y, … tafe cert 3 hairdressing

Lymphoma Study Group of JCOG - Oxford Academic

Category:未治療限局期鼻NK/T細胞リンパ腫に対する放射線治療とDeVIC療 …

Tags:Jcog0211-di

Jcog0211-di

Phase I/II Study of Concurrent Chemoradiotherapy for Localized …

WebUnique ID issued by UMIN: UMIN000007842: Receipt number: R000009236: Scientific Title: A phase I/II study of concurrent chemoradiotherapy (RT-DeVIC) for newly-diagnosed, … Web01 Jan 2013. Phase I/II Study of Concurrent Chemoradiotherapy for Newly-Diagnosed, Localized Nasal NK/T-Cell Lymphoma: Results of a Phase I Portion of JCOG0211-DI

Jcog0211-di

Did you know?

Web3 nov 2016 · Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211 WebPhase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma : Japan clinical oncology group study JCOG0211. / Yamaguchi, Motoko; …

Web3 nov 2016 · Toexplorethepossibilityofmoreeffectiveinductionchemother-apy for NK-cell neoplasms, the NK-Cell Tumor Study Group, com-prising Japanese and Asian hematologists, has ... WebA Phase I/II study (JCOG0211-DI) of concurrent radiotherapy (50 Gy) and three courses of dexamethasone, etoposide, ifosfamide and carboplatin (DeVIC) consisting of multidrug …

WebJCOG0211-DI Coordinating Office Department of Hematology and Oncology, Mie University Graduate School of Medicine 研究費提供組織 / Funding Source 厚生労働省 WebN Maseki's 120 research works with 5,714 citations and 2,818 reads, including: Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: An Updated Analysis of the Japan ...

WebPhase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma : Japan clinical oncology group study JCOG0211. / Yamaguchi, Motoko; Tobinai, Kensei; Oguchi, Masahiko et al. In: Journal of Clinical Oncology, Vol. 27, No. 33, 20.11.2009, p. 5594-5600. Research output: Contribution to journal › Article ...

Web– JCOG0211 (PI/II) – Concurrent chemoradiotherapy (RT-2/3DeVIC) • Newly-diagnosed stage IV, relapsed/refractory NKTCL – NKTSG (Multinational trials in East Asia) – SMILE … tafe cert iii community servicesWeb23 ott 2012 · 山口氏らはJCOG0211-DI試験において、未治療限局期鼻NKTCLでAnn Arbor病期分類IE期または頸部リンパ節浸潤のIIE期の患者を対象に、RT-DeVIC療法を検討した。 tafe cert iv in fine artWebExtranodal NK/T-cell lymphoma, nasal type (ENKL), accounts for less than 3% of malignant lymphomas in Japan. Based on the results of prospective clinical trials, ENKL treatment has dramatically improved during the last decade in Japan. The Lymphoma Study Group of the Japan Clinical Oncology Group (J … tafe cert 4 in training and assessmentWebPhase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. Yamaguchi M, Tobinai K, … tafe cert iii health servicesWeb20 mag 2012 · 8050 Background: Concurrent chemoradiotherapy has been regarded as one of the standard management for localized nasal NKTCL. However, its long-term efficacy … tafe character designWeb5 ott 2009 · Purpose To explore a more effective treatment for localized nasal natural killer (NK)/T-cell lymphoma, we conducted a phase I/II study of concurrent … tafe chc40221WebAfter JCOG0211 study, 49% of RT was designed according to JCOG0211 RT protocol, while 80% or more were not compliant RT protocol before/during JCOG0211. The local control was 74% for all population, 88% of local control rate was observed in patients treated with RT compliant with JCOG0211 RT protocol (extended RT), while 70% in patients tafe cert iii early childhood